cnbc_topnews

AI chipmaker Cerebras targets $3.5 billion raise in IPO

ai chipmaker cerebras filed for an ipo on the nasdaq, aiming to raise up to $3.5 billion. it plans to sell 28 million shares at $115 to $125 each, which could value the company at $26.6 billion. that's up from a $23 billion valuation in a february venture round that included advanced micro devices as an investor.

cerebras first tried to go public in 2024 but withdrew as it shifted from selling hardware to offering cloud services running on its own chips. it filed again in april. the company reported $510 million in revenue for the fourth quarter, up about 76% year over year, with $87.9 million in net income for the period.

in january, cerebras said it would supply up to 750 megawatts of ai computing power to openai through 2028 in a deal worth over $20 billion. ceo andrew feldman isn't selling shares in the ipo. he'll own 10.3 million shares after, worth up to $1.28 billion at the high end of the range. underwriters have an option to buy an additional 4.2 million shares, which could bring in another $525 million.

source: cnbc_topnews
sentiment: +0.70 · impact: 0.50

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

oil started the week higher on a disputed claim of an iranian strike on a u.s. navy ship in the strait of hormuz. the report, which hasn't been confirmed by u.s. officials, added fresh volatility to crude markets. the strait of hormuz is a key chokepoint

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

source: marketwatch_top sentiment: -0.70 · impact: 0.80

Warsh's take on Fed independence is met with confusion and some concern

kevin warsh, trump's pick to lead the fed, is drawing confusion from six former fed officials over his views on fed independence. the sticking point: he draws a line between monetary policy — which he says should be "strictly independent" — and "non-monetary matters" like international

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

the weight-loss and diabetes drug boom is creating a bubble risk for pharma, according to a deloitte report out monday. r&d returns for the top 20 pharma companies hit 7% for a third straight year, driven almost entirely by glp-1 drugs like wegovy and zepbound. strip those out

Read more

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

Warsh's take on Fed independence is met with confusion and some concern

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds